NCT04195750
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 21, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
The 49 most recent of 95 versions: 48 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Sep 17, 2026 to Nov 11, 2026
Notable Eligibility criteria expanded, about 29 words Show 4 more changesShow less
- Study completion date: Sep 17, 2026 to Oct 14, 2026
- Secondary endpoints: details revised at 10 of 11 entries
- Site details revised at 4 of 172 sites
- Publications: details revised at 2 of 2 entries
- Minor Study sites revised (172)v94
Notable Results first posted: Apr 29, 2025v93 Show 4 more changesShow less
- Eligibility criteria revised
- Secondary endpoints revised (11)
- Primary endpoints revised (2)
- Study arms: 2 to 3
- Minor Study completion date: Sep 17, 2025 to Sep 17, 2026v92
Show 44 earlier versionsHide 44 earlier versions
- Study Identification, Study Status, Referencesv91
- Minor Enrollment target: estimated 736 to confirmed 755
- Primary completion date changed from estimate of Sep 17, 2025 to Apr 15, 2024
- Notable Eligibility criteria revisedv88
- Study Identification, Study Status, Outcome Measures, Referencesv87
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 172 of 172 sites
- Minor Site details revised at 6 of 172 sitesv85
- Minor Site details revised at 2 of 172 sitesv84
- Minor Site details revised at 1 of 172 sitesv83
- Minor Site details revised at 3 of 172 sitesv82
- Minor Site details revised at 3 of 172 sitesv81
- Minor Site details revised at 2 of 172 sitesv80
- Minor Site details revised at 3 of 172 sitesv79
- Minor Site details revised at 2 of 172 sitesv78
- Minor Site details revised at 2 of 172 sitesv77
- Minor Site details revised at 5 of 172 sitesv76
- Minor Site details revised at 7 of 172 sitesv75
- Minor Site details revised at 7 of 172 sitesv74
- Minor Site details revised at 11 of 172 sitesv73
- Minor Site details revised at 8 of 172 sitesv72
- Minor Site details revised at 5 of 172 sitesv71
- Minor Site details revised at 4 of 172 sitesv70
- Minor Study sites: 171 to 172v69
- Minor Site details revised at 2 of 171 sitesv68
- Minor Site details revised at 5 of 171 sitesv67
- Minor Study sites: 170 to 171v66
- Minor Site details revised at 4 of 170 sitesv65
- Minor Study sites: 168 to 170v64
- Minor Site details revised at 1 of 168 sitesv63
- Minor Study sites: 167 to 168v62
- Minor Study sites: 166 to 167v61
- Minor Study sites: 164 to 166v60
- Minor Study sites: 163 to 164v59
- Minor Study sites: 162 to 163v58
- Minor Study sites: 160 to 162v57
- Minor Study sites: 154 to 160v56
- Minor Study sites: 151 to 154v55
- Minor Study sites: 148 to 151v54
- Minor Study sites: 144 to 148v53
- Minor Study sites revised (144)v52
- Minor Study sites revised (144)v51
- Minor Site details revised at 2 of 144 sitesv50
- Minor Site details revised at 1 of 144 sitesv49
- Minor Study sites: 143 to 144v48
- Minor Site details revised at 2 of 143 sitesv47
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.
Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.
Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.
Drugs: Belzutifan, Everolimus
Sites
172 sites in 23 countries
United States 29, Japan 23, Russia 11, Italy 10, United Kingdom 9, France 8, Germany 8, Turkey (Türkiye) 8, Canada 6, Czechia 6, Hungary 6, South Korea 6, Taiwan 6, Brazil 5, Colombia 5, Spain 5, Finland 4, Hong Kong 4, Sweden 4, Ukraine 3, Chile 2, Denmark 2, Norway 2